

## WEST Search History

DATE: Monday, November 05, 2007

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L8	L6 and (nicotinic acetylcholine)	5
<input type="checkbox"/>	L7	L6 and l2	1
<input type="checkbox"/>	L6	514/376.icls. or 514/376.ccls. or 548/216.icls. or 548/276.ccls.	1043
<input type="checkbox"/>	L5	L2 and spiro and azabicyclo	1
<input type="checkbox"/>	L4	L2 and (spiro.ti. or spiro.ab.)	2
<input type="checkbox"/>	L3	L2 and (spiro near azabicyclo)	0
<input type="checkbox"/>	L2	L1 and (nicotinic acetylcholine)	24
<input type="checkbox"/>	L1	astrazeneca.as.	1120

END OF SEARCH HISTORY

FILE 'REGISTRY' ENTERED AT 16:02:28 ON 05 NOV 2007

L1           STRUCTURE UPLOADED

L2           22 S L1

L3           340 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:27:47 ON 05 NOV 2007

L4           7 S L3/THU

L5           10 S L3

FILE 'REGISTRY' ENTERED AT 16:50:43 ON 05 NOV 2007

L6           STRUCTURE UPLOADED

L7           3 S L6

L8           45 S L7 SUB=L3 FULL

FILE 'CAPLUS' ENTERED AT 16:51:41 ON 05 NOV 2007

L9           1 S L8

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'REGISTRY' AT 16:25:14 ON 05 NOV 2007  
FILE 'REGISTRY' ENTERED AT 16:25:14 ON 05 NOV 2007  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.80	2.01

=> s l1 sss full  
FULL SEARCH INITIATED 16:27:33 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 599 TO ITERATE

100.0% PROCESSED 599 ITERATIONS 340 ANSWERS  
SEARCH TIME: 00.00.01

L3 340 SEA SSS FUL L1

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	175.25	175.46

FILE 'CAPLUS' ENTERED AT 16:27:47 ON 05 NOV 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Nov 2007 VOL 147 ISS 20  
FILE LAST UPDATED: 4 Nov 2007 (20071104/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3/thu  
10 L3  
950244 THU/RL  
L4 7 L3/THU  
(L3 (L) THU/RL)

=> s l3  
L5 10 L3

=> d l5 1-10 ti abs bib hitstr

L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Modeling Subtype-Selective Agonists Binding with  $\alpha 4\beta 2$  and  
 $\alpha 7$  Nicotinic Acetylcholine Receptors: Effects of Local Binding and  
Long-Range Electrostatic Interactions

AB The subtype-selective binding of 14 representative agonists with  $\alpha 4\beta 2$  and  $\alpha 7$  nicotinic acetylcholine receptors (nAChRs) has been studied by performing homol. modeling, mol. docking, geometry optimizations, and microscopic and phenomenol. binding free energy calcns. All of the computational results demonstrate that the subtype selectivity of the agonists binding with  $\alpha 4\beta 2$  and  $\alpha 7$  nAChRs is affected by both local binding and long-range electrostatic interactions between the receptors and the protonated structures of the agonists. The effects of the long-range electrostatic interactions are mainly due to the distinct difference in the net charge of the ligand-binding domain between the two nAChR subtypes. For the  $\alpha 4\beta 2$ -selective agonists examined, the microscopic binding modes with the  $\alpha 4\beta 2$  nAChR are very similar to the corresponding modes with the  $\alpha 7$  nAChR, and therefore, the subtype selectivity of these agonists binding with  $\alpha 4\beta 2$  and  $\alpha 7$  nAChRs is dominated by the long-range electrostatic interactions. For the  $\alpha 7$ -selective agonists, their microscopic binding modes with the  $\alpha 7$  nAChR are remarkably different from those with the  $\alpha 4\beta 2$  nAChR so that the local binding (including the hydrogen bonding and cation- $\pi$  interactions) with the  $\alpha 7$  nAChR is much stronger than that with the  $\alpha 4\beta 2$  nAChR. The calculated phenomenol. binding free energies are in good agreement with available exptl. data for the relative binding free energies concerning the subtype selectivity of agonists binding with the two different nAChR subtypes. The fundamental insights obtained in the present study should be valuable for future rational design of potential therapeutic agents targeted to specific nAChR subtypes.

AN 2006:1296210 CAPLUS <<LOGINID::20071105>>

DN 146:200413

TI Modeling Subtype-Selective Agonists Binding with  $\alpha 4\beta 2$  and  $\alpha 7$  Nicotinic Acetylcholine Receptors: Effects of Local Binding and Long-Range Electrostatic Interactions

AU Huang, Xiaoqin; Zheng, Fang; Chen, Xi; Crooks, Peter A.; Dwoskin, Linda P.; Zhan, Chang-Guo

CS Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536, USA

SO Journal of Medicinal Chemistry (2006), 49(26), 7661-7674  
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

IT 360043-72-7 360044-45-7

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(subtype selectivity of agonists binding with  $\alpha 4\beta 2$  and  $\alpha 7$  nAChRs is affected by hydrogen bonding, cation- $\pi$  interactions and long-range electrostatic interactions)



RN 360043-72-7 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, 3'-(5-chloro-2-thienyl)-, (3R)- (CA INDEX NAME)

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of spiro-oxazolidinone compounds as nicotinic acetylcholine receptor ligands

GI



AB Title compds. I [Ar1, Ar2 = 5- or 6-membered aromatic or heteroarom. moiety having 0,1 or 2 nitrogen atoms, 0 or 1 oxygen atoms, and 0 or 1 sulfur atoms; wherein Ar1 is unsubstituted or has 1, 2 or 3 substituents selected from alkyl, alkenyl, alkynyl, etc. and Ar2 is unsubstituted or has 1, 2 or 3 substituents selected from -CONR1R2, -NR1COR2; R1, R2 = H, alkyl, or -NR1R2 in combination is -(CH2)<sup>j</sup>G(CH2)<sup>k</sup>-; G = bond, oxygen, sulfur, etc.; j = 2-4; k = 0-2] or stereoisomers, enantiomers, in vivo hydrolysable precursors and pharmaceutically acceptable salts thereof were prepared For example, Pd(PPh3)<sub>4</sub> catalyzed coupling reaction of 4-(N,N-dimethylaminocarbonyl)phenylboronic acid with 2,5-dibromothiophene followed by reaction with (3S)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one afforded compound II. Compds. I are claimed useful as nicotinic acetylcholine receptor ligands for the treatment of anxiety, schizophrenia, etc. (no data).

AN 2006:608651 CAPLUS <<LOGINID::20071105>>

DN 145:83311

TI Preparation of spiro-oxazolidinone compounds as nicotinic acetylcholine receptor ligands

IN Chapdelaine, Marc; Chang, Hui-Fang; Herzog, Keith J.; Horchler, Carey; Phillips, Eifion

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006065209	A1	20060622	WO 2005-SE1909	20051213
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005317280	A1	20060622	AU 2005-317280	20051213
	CA 2591430	A1	20060622	CA 2005-2591430	20051213

EP 1831231 A1 20070912 EP 2005-819091 20051213  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR  
 IN 2007DN04472 A 20070831 IN 2007-DN4472 20070612  
 NO 2007003551 A 20070801 NO 2007-3551 20070709  
 PRAI US 2004-636362P P 20041215  
 US 2005-643319P P 20050112  
 WO 2005-SE1909 W 20051213  
 OS MARPAT 145:83311  
 IT 828929-13-1P 828929-58-4P 828929-60-8P  
 828929-62-0P 828929-65-3P 828929-93-7P  
 892547-89-6P 892547-90-9P 892547-91-0P  
 892547-92-1P 892547-93-2P 892547-94-3P  
 892547-95-4P 892547-96-5P 892547-97-6P  
 892547-98-7P 892547-99-8P 892548-00-4P  
 892548-01-5P 892548-02-6P 892548-04-8P  
 892548-05-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of spiro-oxazolidinone compds. as nicotinic acetylcholine  
 receptor ligands for treatment of anxiety and schizophrenia)  
 RN 828929-13-1 CAPLUS  
 CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
 3'-[5-(2-pyridinyl)-2-thiazolyl]-, (3R)- (CA INDEX NAME)  
 L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI (R)-3'-[3-Methylbenzo[b]thiophen-5-yl]spiro[1-azabicyclo[2,2,2]octane-3,5'-  
 oxazolidin]-2'-one, a Novel and Potent  $\alpha 7$  Nicotinic Acetylcholine  
 Receptor Partial Agonist Displays Cognitive Enhancing Properties  
 AB Recent studies have suggested that the  $\alpha 7$  nicotinic acetylcholine  
 receptors play important roles in learning and memory. Herein, we  
 describe our research of the structure-activity relationships (SAR) in a  
 series of (S)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-ones  
 bearing various bicyclic moieties to discover novel  $\alpha 7$  receptor  
 agonists. Through a number of SAR studies on the series, we have found out  
 that inhibition of CYP 2D6 isoenzyme, which was a primary obstacle for the  
 previously identified compound, was avoidable by the introduction of  
 bicyclic moieties. Chemical optimization of the series led to the  
 identification of a novel and potent  $\alpha 7$  nicotinic acetylcholine  
 receptor partial agonist 23. This compound not only possessed high binding  
 affinity ( $K_i = 3$  nmol/L) toward the  $\alpha 7$  receptor but also showed  
 agonistic activity even at a concentration of 0.1  $\mu$ mol/L. In addition,  
 compound 23  
 improved cognition in several rat models, which might suggest the  
 potential of the  $\alpha 7$  receptor partial agonist for the treatment of  
 neurol. disorders including cognitive dysfunction.  
 AN 2006:600073 CAPLUS <<LOGINID::20071105>>  
 DN 145:159084  
 TI (R)-3'-[3-Methylbenzo[b]thiophen-5-yl]spiro[1-azabicyclo[2,2,2]octane-3,5'-  
 oxazolidin]-2'-one, a Novel and Potent  $\alpha 7$  Nicotinic Acetylcholine  
 Receptor Partial Agonist Displays Cognitive Enhancing Properties  
 AU Tatsumi, Ryo; Fujio, Masakazu; Takanashi, Shin-Ichi; Numata, Atsushi;  
 Katayama, Jiro; Satoh, Hiroyuki; Shiigi, Yasuyuki; Maeda, Jun-Ichi;  
 Kuriyama, Makoto; Horikawa, Takashi; Murozono, Takahiro; Hashimoto, Kenji;  
 Tanaka, Hiroshi  
 CS Pharmaceuticals Research Unit, Research & Development Division, Mitsubishi  
 Pharma Corporation, Kanagawa, 227-0033, Japan  
 SO Journal of Medicinal Chemistry (2006), 49(14), 4374-4383  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 145:159084


IT 360043-53-4P 360043-86-3P 360043-87-4P  
 360043-90-9P 360044-00-4P 360044-01-5P  
 360044-02-6P 360044-04-8P 360044-10-6P  
 360044-12-8P 360044-14-0P 360044-21-9P  
 360044-41-3P 360044-44-6P 501901-83-3P  
 501901-91-3P 900508-72-7P 900508-73-8P  
 900508-74-9P 900508-75-0P 900508-76-1P  
 900508-77-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (Nicotinic Acetylcholine Receptor Partial Agonists Display Cognitive  
 Enhancing Properties)

RN 360043-53-4 CAPLUS  
 CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
 3'-benzo[b]thien-5-yl-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Synthesis and evaluation of [125I]I-TSA as a brain nicotinic acetylcholine  
 receptor  $\alpha 7$  subtype imaging agent  
 AB Introduction: Some in vitro investigations have suggested that the  
 nicotinic acetylcholine receptor (nAChR)  $\alpha 7$  subtype is implicated in  
 Alzheimer's disease, schizophrenia and others. Recently, we developed  
 (R)-3'-(5-bromothiophen-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-  
 [1',3']oxazolidin]-2'-one (Br-TSA), which has a high affinity and  
 selectivity for  $\alpha 7$  nAChRs. Therefore we synthesized  
 (R)-3'-(5-[125I]iodothiophen-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-  
 [1',3']oxazolidin]-2'-one ([125I]I-TSA) and evaluated its potential for  
 the in vivo detection of  $\alpha 7$  nAChR in brain. Methods: In vitro  
 binding affinity of I-TSA was measured in rat brain homogenates.  
 Radioiodination was accomplished by a Br-I exchange reaction.  
 Biodistribution studies were undertaken in mice by tail vein injection of  
 [125I]I-TSA. In vivo receptor blocking studies were carried out by  
 treating mice with methyllycaconitine (MLA; 5 nmol/5  $\mu$ l, i.c.v.) or  
 nonradioactive I-TSA (50  $\mu$ mol/kg, i.v.). Results: I-TSA exhibited a  
 high affinity and selectivity for the  $\alpha 7$  nAChR ( $K_i$  for  $\alpha 7$   
 nAChR=0.54 nM). Initial uptake in the brain was high (4.42 %dose/g at 5  
 min), and the clearance of radioactivity was relatively slow in the  
 hippocampus ( $\alpha 7$  nAChR-rich region) and was rather rapid in the  
 cerebellum ( $\alpha 7$  nAChR poor region). The hippocampus to cerebellum  
 uptake ratio was 0.9 at 5 min postinjection, but it was increased to 1.8  
 at 60 min postinjection. Although the effect was not statistically  
 significant, administration of I-TSA and MLA decreased the accumulation of  
 radioactivity in hippocampus. Conclusion: Despite its high affinity and  
 selectivity, [125I]I-TSA does not appear to be a suitable tracer for in  
 vivo  $\alpha 7$  nAChR receptor imaging studies due to its high nonspecific  
 binding. Further structural optimization is needed.

AN 2006:365732 CAPLUS <<LOGINID::20071105>>  
 DN 145:433949  
 TI Synthesis and evaluation of [125I]I-TSA as a brain nicotinic acetylcholine  
 receptor  $\alpha 7$  subtype imaging agent  
 AU Ogawa, Mikako; Tatsumi, Ryo; Fujio, Masakazu; Katayama, Jiro; Magata,  
 Yasuhiro  
 CS Laboratory of Genome Bio-Photonics, Photon Medical Research Center,  
 Hamamatsu Medical University, Hamamatsu, 431-3192, Japan  
 SO Nuclear Medicine and Biology (2006), 33(3), 311-316  
 CODEN: NMBIEO; ISSN: 0969-8051  
 PB Elsevier Inc.  
 DT Journal  
 LA English  
 IT 360043-74-9  
 RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological  
 study); RACT (Reactant or reagent)  
 (affinities of I-TSA, Br-TSA, and TSA for brain nicotinic acetylcholine

receptor  $\alpha 7$  and 5-HT3 receptor)  
 RN 360043-74-9 CAPLUS  
 CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
 3'-(5-bromo-2-thienyl)-, (3R)- (CA INDEX NAME)  
 L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Benzothiazolnylazabicyclooctane analogs as selective  $\alpha 7$  nicotinic  
 receptor ligands for PET diagnosis of brain diseases  
 GI



I



II

AB Benzothiazolnylazabicyclooctane analogs (I and II; R = radionuclide) are  
 claimed as selective  $\alpha 7$  nicotinic receptor ligands for PET diagnosis  
 of brain diseases. The benzothiazolnylazabicyclooctane analogs were  
 prepared, and their brain distributions were studied.

AN 2006:267108 CAPLUS <<LOGINID::20071105>>  
 DN 144:327037

TI Benzothiazolnylazabicyclooctane analogs as selective  $\alpha 7$  nicotinic  
 receptor ligands for PET diagnosis of brain diseases

IN Matsuo, Masaaki; Kitashoji, Takeshi; Kamitsuchi, Eiji; Tsukada, Hideo;  
 Nishiyama, Shingo

PA Nard Institute Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 27 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006076891	A	20060323	JP 2004-259669	20040907
PRAI	JP 2004-259669		20040907		

OS MARPAT 144:327037

IT 880090-84-6P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); RCT (Reactant); SPN  
 (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT  
 (Reactant or reagent); USES (Uses)

(benzothiazolnylazabicyclooctane analogs as selective  $\alpha 7$  nicotinic  
 receptor ligands for PET diagnosis of brain diseases)

RN 880090-84-6 CAPLUS


CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
 3'-[5-(tributylstannyl)-2-thienyl]-, (3R)- (CA INDEX NAME)

L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Discovery of the  $\alpha 7$  Nicotinic Acetylcholine Receptor Agonists.  
 (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-  
 [1',3']oxazolidin-2'-one as a Novel, Potent, Selective, and Orally  
 Bioavailable Ligand

GI





I

AB Recent advances in mol. biol. suggest that neuronal nicotinic acetylcholine receptors play important roles in the central nervous system (CNS). Of these receptors, the  $\alpha 7$  group has recently attracted interest for its CNS-related actions and is looked to as a potential new class of pharmacol. targets for cognition, schizophrenia, sensory gating, and anxiety. In the course of a research program aimed at the discovery of  $\alpha 7$  receptor agonists with high affinity, subtype selectivity, and good pharmacokinetic profile, we discovered (R)-3'-(5-chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one (I). Compound I has potent binding affinity ( $K_i = 9$  nmol/L) and good selectivity toward the other nicotinic subtypes ( $\alpha 4\beta 2$  and  $\alpha 1\beta 2\gamma 8$ ) and has been found in pharmacokinetic evaluation to have good oral bioavailability and brain permeability.

AN 2005:164962 CAPLUS <<LOGINID::20071105>>

DN 142:385073

TI Discovery of the  $\alpha 7$  Nicotinic Acetylcholine Receptor Agonists. (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one as a Novel, Potent, Selective, and Orally Bioavailable Ligand

AU Tatsumi, Ryo; Fujio, Masakazu; Satoh, Hiroyuki; Katayama, Jiro; Takanashi, Shinichi; Hashimoto, Kenji; Tanaka, Hiroshi

CS Pharmaceuticals Research Unit, Research Development Division, Mitsubishi Pharma Corporation, Yokohama, Kanagawa, 227-0033, Japan

SO Journal of Medicinal Chemistry (2005), 48(7), 2678-2686  
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 142:385073


IT 360043-73-8P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
((R)-3'-(5-chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one preparation as oral  $\alpha 7$  nicotinic receptor agonists)

RN 360043-73-8 CAPLUS



CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, 3'-(5-chloro-2-thienyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT 360043-35-2P 360043-36-3P 360043-38-5P  
 360043-40-9P 360043-54-5P 360043-55-6P  
 360043-56-7P 360043-57-8P 360043-59-0P  
 360043-62-5P 360043-64-7P 360043-66-9P  
 360043-67-0P 360043-69-2P 360043-71-6P  
 360043-74-9P 360043-76-1P 360043-77-2P  
 360043-79-4P 360043-98-7P 360044-22-0P  
 849637-48-5P  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 ((R)-3'-(5-chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-  
 [1',3']oxazolidin-2'-one preparation as oral  $\alpha 7$  nicotinic receptor  
 agonists)  
 RN 360043-35-2 CAPLUS  
 CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
 3'-(2-naphthalenyl)-, (3R)- (CA INDEX NAME)  
 L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI A preparation of derivatives of oxazolidinone with affinity to the  
 $\alpha 7$ -nicotinic acetylcholine receptor  
 GI



AB The invention relates to a preparation of derivs. of oxazolidinone of formula  
 Q-X-A-Y [wherein: Q is spiro(azabicyclooctanoxazolidinone) derivative; A is O,  
 S, or NH, etc.; X is 5- or 6-membered heterocycle; Y is 5- or  
 6-membered (hetero)aromatic ring] with affinity to the  $\alpha 7$ -nicotinic  
 acetylcholine receptor. For instance, oxazolidinone derivative I was prepared  
 via phenylation of II by phenylboronic acid. The compds. of the invention  
 were screened in  $\alpha 7$  nAChR subtype affinity assay and showed binding

affinities (Ki) of less than 1000 nM.

AN 2005:58211 CAPLUS <<LOGINID::20071105>>

DN 142:155977

TI A preparation of derivatives of oxazolidinone with affinity to the  
 $\alpha$ 7-nicotinic acetylcholine receptor

IN Chang, Hui-Fang; Phillips, Eifion

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited


SO PCT Int. Appl., 77 pp.  
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005005435	A1	20050120	WO 2004-GB2904	20040706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004255920	A1	20050120	AU 2004-255920	20040706
	CA 2531510	A1	20050120	CA 2004-2531510	20040706
	EP 1654264	A1	20060510	EP 2004-743249	20040706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1829721	A	20060906	CN 2004-80021849	20040706
	BR 2004012382	A	20060919	BR 2004-12382	20040706
	JP 2007516200	T	20070621	JP 2006-518343	20040706
	US 2006154945	A1	20060713	US 2006-563271	20060104
	MX 2006PA00231	A	20060411	MX 2006-PA231	20060105
	NO 2006000612	A	20060406	NO 2006-612	20060208
PRAI	US 2003-485523P	P	20030708		
	WO 2004-GB2904	W	20040706		
OS	CASREACT 142:155977; MARPAT 142:155977				
IT	828929-12-0P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES' (Uses) (preparation of azabicyclooctane derivs. with affinity to the $\alpha$ 7-nicotinic acetylcholine receptor)				
RN	828929-12-0 CAPLUS				
CN	Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, 3'-[5-(2-pyridinyl)-2-thiazolyl]- (CA INDEX NAME)				



IT 828928-73-0P 828928-74-1P 828928-75-2P  
 828928-76-3P 828928-77-4P 828928-78-5P

828928-79-6P 828928-80-9P 828928-81-0P  
828928-82-1P 828928-83-2P 828928-84-3P  
828928-85-4P 828928-86-5P 828928-87-6P  
828928-89-8P 828928-90-1P 828928-91-2P  
828928-92-3P 828928-93-4P 828928-94-5P  
828928-95-6P 828928-96-7P 828928-97-8P  
828928-98-9P 828928-99-0P 828929-00-6P  
828929-01-7P 828929-02-8P 828929-03-9P  
828929-05-1P 828929-07-3P 828929-10-8P  
828929-11-9P 828929-13-1P 828929-14-2P  
828929-15-3P 828929-17-5P 828929-18-6P  
828929-19-7P 828929-20-0P 828929-21-1P  
828929-22-2P 828929-23-3P 828929-24-4P  
828929-25-5P 828929-26-6P 828929-27-7P  
828929-28-8P 828929-29-9P 828929-30-2P  
828929-31-3P 828929-32-4P 828929-33-5P  
828929-34-6P 828929-35-7P 828929-36-8P  
828929-37-9P 828929-38-0P 828929-39-1P  
828929-40-4P 828929-41-5P 828929-42-6P  
828929-43-7P 828929-44-8P 828929-45-9P  
828929-46-0P 828929-47-1P 828929-48-2P  
828929-49-3P 828929-50-6P 828929-51-7P  
828929-52-8P 828929-53-9P 828929-54-0P  
828929-55-1P 828929-56-2P 828929-57-3P  
828929-58-4P 828929-59-5P 828929-60-8P  
828929-61-9P 828929-62-0P 828929-63-1P  
828929-64-2P 828929-65-3P 828929-66-4P  
828929-67-5P 828929-68-6P 828929-69-7P  
828929-70-0P 828929-71-1P 828929-72-2P  
828929-73-3P 828929-74-4P 828929-75-5P  
828929-76-6P 828929-77-7P 828929-78-8P  
828929-79-9P 828929-80-2P 828929-81-3P  
828929-82-4P 828929-83-5P 828929-84-6P  
828929-85-7P 828929-86-8P 828929-87-9P  
828929-88-0P 828929-89-1P 828929-90-4P  
828929-91-5P 828929-92-6P 828929-93-7P  
828929-94-8P 828929-95-9P 828929-96-0P  
828929-97-1P 828929-98-2P 828929-99-3P  
828930-00-3P 828930-01-4P 828930-02-5P  
828930-03-6P 828930-04-7P 828930-05-8P  
828930-06-9P 828930-07-0P 828930-08-1P  
828930-09-2P 828930-10-5P 828930-11-6P  
828930-12-7P 828930-13-8P 828930-14-9P  
828930-15-0P 828930-16-1P 828930-17-2P  
828930-18-3P 828930-19-4P 828930-20-7P  
828930-21-8P 828930-22-9P 828930-23-0P  
828930-24-1P 828930-25-2P 828930-26-3P  
828930-27-4P 828930-28-5P 828930-29-6P  
828930-30-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of azabicyclooctane derivs. with affinity to the  
 $\alpha 7$ -nicotinic acetylcholine receptor)


RN 828928-73-0 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
3'-(5-phenyl-2-thienyl)-, (3R)- (CA INDEX NAME)

L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of spiro compounds, their use as  $\alpha 7$  nicotinic receptor  
(partial) agonists, and their pharmaceutical compositions for treatment of  
mental disorders

GI



I

AB Title compds. I (R1 = H, Me, Et, Ac, Cl, Br, CH2OH; R2 = H, Me, Et, Ac, cyano, Br, CH2OH; R3, R4 = none or O), their optical isomers, pharmacol. acceptable salts, or hydrates, useful for treatment of recognition disorder, dementia, schizophrenia, and attention-deficient disorder, are prepared Thus, condensation of 5-bromo-2-methyl-3-(2-methyl-1,3-dioxolan-2-yl)benzo[b]thiophene with (S)-(-)-spiro(1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one) and treatment of the product with concentrated HCl in EtOH gave I (R1 = Me, R2 = Ac, R3 = R4 = none) HCl salt 1/5 hydrate, which showed high affinity to  $\alpha 7$ -nicotinic receptor with Ki value of 14 nM.

AN 2003:216949 CAPLUS <<LOGINID::20071105>>

DN 138:238031

TI Preparation of spiro compounds, their use as  $\alpha 7$  nicotinic receptor (partial) agonists, and their pharmaceutical compositions for treatment of mental disorders

IN Fujio, Masakazu; Katayama, Jiro; Takanashi, Shinichi; Numata, Atsushi

PA Mitsubishi Welfarma Co., Japan

SO Jpn. Kokai Tokkyo Koho, 15 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003081978	A	20030319	JP 2001-273483	20010910
PRAI	JP 2001-273483		20010910		
IT	501901-82-2P 501901-83-3P 501901-84-4P 501901-85-5P 501901-86-6P 501901-87-7P 501901-88-8P 501901-89-9P 501901-90-2P 501901-91-3P 501901-92-4P 501901-93-5P 501901-94-6P 501901-95-7P 501902-05-2P				
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of spiro compds. as $\alpha 7$ nicotinic receptor (partial) agonists and psychotropic drugs)				
RN	501901-82-2	CAPLUS			
CN	Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, 3'-(3-acetyl-2-methylbenzo[b]thien-5-yl)-, (3R)- (CA INDEX NAME)				

Absolute stereochemistry.

L5 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and

analogs as  $\alpha$ -7 nicotinic receptor agonists

AB The title compds. I [X = O, etc.; Y = O, etc.; R1 = H, alkyl, etc.; A = (CH<sub>2</sub>)<sub>m</sub>; m = 2 or 3; T = (CH<sub>2</sub>)<sub>n</sub>; n = 1 or 2; Ar = (un)substituted aromatic heterocyclic ring, etc.] are prepared I are remedies for dementia (e.g., Alzheimer disease), schizophrenia, cognition disorder, etc. Processes for preparing I are claimed in addnl. claims. In an in vitro test for affinity for the  $\alpha$ -7 nicotinic receptors, (R)-3'-(5-bromo-2-thienyl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin-2'-one] showed the K<sub>i</sub> value of 4 nM. Formulations are given.

AN 2001:752491 CAPLUS <<LOGINID::20071105>>

Correction of: 2001:676769

DN 135:318499

Correction of: 135:242223

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as  $\alpha$ -7 nicotinic receptor agonists

IN Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi

PA Welfide Corporation, Japan

SO PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	WO 2001066546	A1	20010913	WO 2001-JP1793	20010307
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2000-65545	A	20000309		
IT	360043-34-1P	360043-35-2P	360043-36-3P		
	360043-37-4P	360043-38-5P	360043-39-6P		
	360043-40-9P	360043-41-0P	360043-42-1P		
	360043-43-2P	360043-44-3P	360043-45-4P		
	360043-46-5P	360043-47-6P	360043-48-7P		
	360043-49-8P	360043-50-1P	360043-51-2P		
	360043-52-3P	360043-53-4P	360043-54-5P		
	360043-55-6P	360043-56-7P	360043-57-8P		
	360043-58-9P	360043-59-0P	360043-60-3P		
	360043-61-4P	360043-62-5P	360043-63-6P		
	360043-64-7P	360043-65-8P	360043-66-9P		
	360043-67-0P	360043-68-1P	360043-69-2P		
	360043-70-5P	360043-71-6P	360043-72-7P		
	360043-73-8P	360043-74-9P	360043-75-0P		
	360043-76-1P	360043-77-2P	360043-78-3P		
	360043-79-4P	360043-80-7P	360043-81-8P		
	360043-82-9P	360043-83-0P	360043-84-1P		
	360043-85-2P	360043-86-3P	360043-87-4P		
	360043-88-5P	360043-89-6P	360043-90-9P		
	360043-91-0P	360043-92-1P	360043-93-2P		
	360043-94-3P	360043-95-4P	360043-96-5P		
	360043-97-6P	360043-98-7P	360043-99-8P		
	360044-00-4P	360044-01-5P	360044-02-6P		
	360044-03-7P	360044-04-8P	360044-05-9P		
	360044-06-0P	360044-07-1P	360044-08-2P		
	360044-09-3P	360044-10-6P	360044-11-7P		
	360044-12-8P	360044-13-9P	360044-14-0P		
	360044-15-1P	360044-16-2P	360044-17-3P		
	360044-18-4P	360044-19-5P	360044-20-8P		

360044-21-9P 360044-22-0P 360044-38-8P  
360044-39-9P 360044-40-2P 360044-41-3P  
360044-42-4P 360044-43-5P 360044-44-6P  
360044-45-7P 360044-46-8P 360044-72-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spiro[azabicycloalkane-oxazolidinone] derivs. and analogs as  $\alpha$ -7 nicotinic receptor agonists)


RN 360043-34-1 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
3'-(2-naphthalenyl)- (CA INDEX NAME)

L5 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as  $\alpha$ -7 nicotinic receptor agonists

GI



AB The title compds. I [X = O, etc.; Y = O, etc.; R1 = H, alkyl, etc.; A = (CH<sub>2</sub>)<sub>m</sub>; m = 2 or 3; T = (CH<sub>2</sub>)<sub>n</sub>; n = 1 or 2; Ar = (un)substituted aromatic heterocyclic ring, etc.] are prepared I are remedies for dementia (e.g., Alzheimer disease), schizophrenia, cognition disorder, etc. Processes for preparing I are claimed in addnl. claims. In an in vitro test for affinity for the  $\alpha$ -7 nicotinic receptors, (R)-3'-(5-bromo-2-thienyl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin-2'-one] showed the K<sub>i</sub> value of 4 nM. Formulations are given.

AN 2001:676769 CAPLUS <<LOGINID::20071105>>

DN 135:242223

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as  $\alpha$ -7 nicotinic receptor agonists

IN Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi

PA Welfide Corporation, Japan

SO PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DT

Japanese

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066546 A1		20010913	WO 2001-JP1793	20010307
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR				

PRAI JP 2000-65545 20000309

OS MARPAT 135:242223

IT 360043-34-1P 360043-35-2P 360043-36-3P


360043-37-4P 360043-38-5P 360043-39-6P  
 360043-40-9P 360043-41-0P 360043-42-1P  
 360043-43-2P 360043-44-3P 360043-45-4P  
 360043-46-5P 360043-47-6P 360043-48-7P  
 360043-49-8P 360043-50-1P 360043-51-2P  
 360043-52-3P 360043-53-4P 360043-54-5P  
 360043-55-6P 360043-56-7P 360043-57-8P  
 360043-58-9P 360043-59-0P 360043-60-3P  
 360043-61-4P 360043-62-5P 360043-63-6P  
 360043-64-7P 360043-65-8P 360043-66-9P  
 360043-67-0P 360043-68-1P 360043-69-2P  
 360043-70-5P 360043-71-6P 360043-72-7P  
 360043-73-8P 360043-74-9P 360043-75-0P  
 360043-76-1P 360043-77-2P 360043-78-3P  
 360043-79-4P 360043-80-7P 360043-81-8P  
 360043-82-9P 360043-83-0P 360043-84-1P  
 360043-85-2P 360043-86-3P 360043-87-4P  
 360043-88-5P 360043-89-6P 360043-90-9P  
 360043-91-0P 360043-92-1P 360043-93-2P  
 360043-94-3P 360043-95-4P 360043-96-5P  
 360043-97-6P 360043-98-7P 360043-99-8P  
 360044-00-4P 360044-01-5P 360044-02-6P  
 360044-03-7P 360044-04-8P 360044-05-9P  
 360044-06-0P 360044-07-1P 360044-08-2P  
 360044-09-3P 360044-10-6P 360044-11-7P  
 360044-12-8P 360044-13-9P 360044-14-0P  
 360044-15-1P 360044-16-2P 360044-17-3P  
 360044-18-4P 360044-19-5P 360044-20-8P  
 360044-21-9P 360044-22-0P 360044-38-8P  
 360044-39-9P 360044-40-2P 360044-41-3P  
 360044-42-4P 360044-43-5P 360044-44-6P  
 360044-45-7P 360044-46-8P 360044-72-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spiro[azabicycloalkane-oxazolidinone] derivs. and analogs as  $\alpha$ -7 nicotinic receptor agonists)

RN 360043-34-1 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
 3'-(2-naphthalenyl)- (CA INDEX NAME)



RN 360043-35-2 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
 3'-(2-naphthalenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

56.12

231.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

ENTRY

TOTAL

SESSION



CA SUBSCRIBER PRICE -7.80 -7.80

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 16:29:45 ON 05 NOV 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 16:50:23 ON 05 NOV 2007  
FILE 'CAPLUS' ENTERED AT 16:50:23 ON 05 NOV 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	56.12	231.58
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.80	-7.80

=> file registry

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	56.59	232.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.80	-7.80

FILE 'REGISTRY' ENTERED AT 16:50:43 ON 05 NOV 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 NOV 2007 HIGHEST RN 952404-20-5  
DICTIONARY FILE UPDATES: 4 NOV 2007 HIGHEST RN 952404-20-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10563271narrower.str



```

chain nodes :
9 14 46 47 48
ring nodes :
1 2 3 4 5 6 7 8 10 11 12 13 15 16 17 18 19 20 21 22 23 24 25
26 27 28 29 30 40 41 42 43 44
chain bonds :
4-9 11-14 12-40 42-46 47-48
ring bonds :
1-2 1-6 1-7 2-3 3-4 4-5 4-8 5-6 5-10 5-13 7-8 10-11 11-12 12-13 15-16
15-19 16-17 17-18 18-19 20-21 20-25 21-22 22-23 23-24 24-25 26-27 26-30
27-28 28-29
29-30 40-41 40-44 41-42 42-43 43-44
exact/norm bonds :
1-2 1-6 1-7 2-3 3-4 4-5 4-8 4-9 5-6 5-10 5-13 7-8 10-11 11-12 11-14
12-13 12-40 15-16 15-19 16-17 17-18 18-19 20-21 20-25 21-22 22-23 23-24
24-25 26-27
26-30 27-28 28-29 29-30 40-41 40-44 41-42 42-43 42-46 43-44 47-48

```

G1:C,N

G2:O,S,N

G3:[\*1],[\*2],[\*3],[\*4]

G4:C,O,S,N

G5:[\*1],[\*2],[\*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:Atom  
11:Atom 12:Atom 13:Atom 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom  
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom  
40:CLASS 41:Atom  
42:Atom 43:Atom 44:Atom 46:Atom 47:Atom 48:Atom

L6 STRUCTURE UPLOADED

=> d l6

L6 HAS NO ANSWERS

L6 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l6

SAMPLE SEARCH INITIATED 16:51:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 5 TO 234

PROJECTED ANSWERS: 3 TO 163

L7 3 SEA SSS SAM L6


=> d l7 scan

L7 3 ANSWERS ' REGISTRY COPYRIGHT 2007 ACS on STN

IN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
3'-[5-(2-thiazolyl)-3-thienyl]-, (3R)-

MF C16 H17 N3 O2 S2

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L7 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
3'-(5-phenyl-3-furanyl)-, (3R)-  
MF C19 H20 N2 O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L7 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
3'-[4-(2-thiazolyl)-2-thienyl]-, (3R)-  
MF C16 H17 N3 O2 S2

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s 17 sub=13

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full  
FULL SUBSET SEARCH INITIATED 16:51:29 FILE 'REGISTRY'  
FULL SUBSET SCREEN SEARCH COMPLETED - 65 TO ITERATE

100.0% PROCESSED 65 ITERATIONS  
SEARCH TIME: 00.00.01


45 ANSWERS

L8 45 SEA SUB=L3 SSS FUL L6

=> d 18 scan

L8 45 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
3'-[4-(3-pyridinyl)-2-thienyl]-, (3R)-  
MF C18 H19 N3 O2 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L8 45 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
3'-[5-(5-thiazolyl)-3-furanyl]-, (3R)-  
MF C16 H17 N3 O3 S


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L8 45 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
3'-[5-(2-thiazolyl)-3-furanyl]-, (3R)-  
MF C16 H17 N3 O3 S


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L8 45 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN . Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one,  
 3'-[2,2'-bifuran]-4-yl-, (3R)-  
 MF C17 H18 N2 O4

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
41.55	273.60

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-7.80

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 16:51:41 ON 05 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Nov 2007 VOL 147 ISS 20

FILE LAST UPDATED: 4 Nov 2007 (20071104/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 18



L9 1 L8

=> d 19 ti abs bib

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

TI A preparation of derivatives of oxazolidinone with affinity to the  
 $\alpha$ 7-nicotinic acetylcholine receptor

GI



AB The invention relates to a preparation of derivs. of oxazolidinone of formula Q-X-A-Y [wherein: Q is spiro(azabicyclooctanoxazolidinone) derivative; A is O, S, or NH, etc.; X is 5- or 6-membered heterocycle; Y is 5- or 6-membered (hetero)aromatic ring] with affinity to the  $\alpha$ 7-nicotinic acetylcholine receptor. For instance, oxazolidinone derivative I was prepared via phenylation of II by phenylboronic acid. The compds. of the invention were screened in  $\alpha$ 7 nAChR subtype affinity assay and showed binding affinities ( $K_i$ ) of less than 1000 nM.

AN 2005:58211 CAPLUS <<LOGINID::20071105>>

DN 142:155977

TI A preparation of derivatives of oxazolidinone with affinity to the  
 $\alpha$ 7-nicotinic acetylcholine receptor

IN Chang, Hui-Fang; Phillips, Eifion

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005005435	A1	20050120	WO 2004-GB2904	20040706
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,			

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

AU 2004255920	A1	20050120	AU 2004-255920	20040706
CA 2531510	A1	20050120	CA 2004-2531510	20040706
EP 1654264	A1	20060510	EP 2004-743249	20040706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1829721	A	20060906	CN 2004-80021849	20040706
BR 2004012382	A	20060919	BR 2004-12382	20040706
JP 2007516200	T	20070621	JP 2006-518343	20040706
US 2006154945	A1	20060713	US 2006-563271	20060104
MX 2006PA00231	A	20060411	MX 2006-PA231	20060105
NO 2006000612	A	20060406	NO 2006-612	20060208
PRAI US 2003-485523P	P	20030708		
WO 2004-GB2904	W	20040706		

OS CASREACT 142:155977; MARPAT 142:155977

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT